Coverage-gated living condition brief

Prostate Cancer peptide evidence brief

A cited Prostate Cancer peptide evidence brief across 57 exact-label ClinicalTrials.gov records, 6 connected profiles, and 16 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

57 selected records.

Connected peptides

6 profiles.

Registry update years

2010–2026 in selected records.

Direct collection answer · published August 17, 2026

What peptide evidence does PeptideScanner carry for Prostate Cancer?

PeptideScanner’s selected collection contains 57 retained ClinicalTrials.gov records carrying the exact condition label “Prostate Cancer,” connected to 6 peptide profiles across 16 registry-update years.

That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Prostate Cancer, and it is not a safety or efficacy assessment.

Indication intelligence

Selected evidence landscape

Trial phases4

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses3

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 277 selected PubMed records and 38 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Prostate Cancer unless their own cited source says so.

Related profile context

Literature connected through these peptide profiles

All literature facets →

This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Prostate Cancer.

Degarelix · source record 2026-11-17

Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques.

PubMed lists PMID 43041099 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2027-01 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Leuprolide · source record 2026-11-06

Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy.

PubMed lists PMID 42962871 in Physiology & behavior as Journal Article, with publication-date metadata of 2026-10-30 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Goserelin · source record 2026-08-13

Roles of Goserelin in Gynecological Disorders.

PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Triptorelin · source record 2026-11-09

Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.

PubMed lists PMID 25990480 in Archives of gynecology and obstetrics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2015-05-20 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Pasireotide · source record 2026-10-31

Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.

PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT00003026

PeptideScanner retained ClinicalTrials.gov record NCT00003026 at 2026-11-15T21:49:16.513Z. Its registry update date was 2012-07-02, and PeptideScanner's reviewed identity mapping was triptorelin.

PeptideScanner change date
November 15, 2026
Cited source date
July 2, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00004124

PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
December 30, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00005044

PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
June 15, 2022
Evidence lane
Clinical trials

Exact-record source chronology

Prostate Cancer registry timeline

All trial facets →

Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.

2026

8 records

2025

5 records

2024

3 records

2023

3 records

2022

2 records

2021

2 records

2019

2 records

2018

2 records

2017

4 records

2016

3 records

2015

4 records

2014

4 records

2013

6 records

2012

3 records

2011

3 records

2010

3 records
What this brief cannot answer